Patent · US Active

Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)

US11827910B2 · kind B2 · utility

0Cited by
65References
23Claims
0Family size

Assignees

Inventors

Key dates

Filing dateFeb 5, 2021
Grant dateNov 28, 2023
Priority date
Expiry dateFeb 17, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2810/85
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.